U.S was Amgen’s largest region in fiscal 2025, bringing in $26.42B of $36.75B (72%).
| Geography | FY 2009 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $18.60B | $19.81B | $23.86B | $26.42B | ||||||||||||
| Us | — | — | — | — | ||||||||||||
| United States | — | — | — | — | ||||||||||||
| Row | $7.73B | $8.38B | $9.56B | $10.33B | ||||||||||||
| Rest Of The World (Row) | — | — | — | — | ||||||||||||
| International | — | — | — | — | ||||||||||||
| Salesrevenuegoodsnet | — | — | — | — | ||||||||||||
| Total | $26.32B | $28.19B | $33.42B | $36.75B |
Amgen brought in $36.75B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 10.0% from $33.42B in fiscal 2024. U.S was the largest at $26.42B (71.9%), ahead of Row at $10.33B (28.1%).
Compared with fiscal 2024, U.S grew 10.7% to $26.42B and Row grew 8.1% to $10.33B. From fiscal 2022 to 2025, combined revenue from these regions grew from $26.32B to $36.75B, a compound annual growth rate of 11.8%. U.S's share of the total rose from 70.6% to 71.9%.
Mckesson Corporation was Amgen’s largest revenue line in fiscal 2024, bringing in $22.17B of $33.45B (66%).
| Customer | FY 2024 |
|---|---|
| Mckesson Corporation | $22.17B |
| Cardinal Health, Inc | $11.28B |
| Total | $33.45B |
Amgen brought in $33.45B from its two revenue lines in fiscal 2024, the year ended December 31, 2024. Mckesson Corporation was the largest at $22.17B (66.3%), ahead of Cardinal Health, Inc at $11.28B (33.7%).
Product Sales was Amgen’s largest product and service line in fiscal 2022, bringing in $17.74B of $26.32B (67%).
| Product and Service | FY 2009 | FY 2011 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| Product Sales | — | — | — | $17.74B | ||||
| Other Products | $4.74B | $5.37B | $5.71B | — | ||||
| Enbrel | — | — | $4.47B | $4.04B | ||||
| Enbrel® (Etanercept) | $5.23B | $5.00B | — | — | ||||
| Neulasta® (Pegfilgrastim) | $3.22B | $2.29B | — | — | ||||
| Neulasta | — | — | — | — | ||||
| Prolia | — | — | $3.25B | — | ||||
| Prolia® (Denosumab) | $2.67B | $2.76B | — | — | ||||
| Aranesp | — | — | $1.48B | — | ||||
| Aranesp® (Darbepoetin Alfa) | $1.73B | $1.57B | — | — | ||||
| Epogen® (Epoetin Alfa) | — | — | — | — | ||||
| Epogen | — | — | — | — | ||||
| Xgeva | — | — | $2.02B | $1.48B | ||||
| Xgeva® (Denosumab) | $1.94B | $1.90B | — | — | ||||
| Otezla | $178.00M | $2.20B | $2.25B | — | ||||
| Neupogen | — | — | — | — | ||||
| Other Revenues | $1.16B | $1.18B | $1.68B | $852.00M | ||||
| Other | — | — | — | — | ||||
| Kyprolis | $1.04B | $1.07B | $1.11B | $850.00M | ||||
| Sensipar® / Mimpara® (Cinacalcet) | — | — | — | — | ||||
| Sensipar Mimpara | — | — | — | — | ||||
| Repatha | — | — | $1.12B | — | ||||
| Repatha (Evolocumab) | $661.00M | $887.00M | — | — | ||||
| Nplate | $795.00M | $850.00M | $1.03B | $848.00M | ||||
| Vectibix | — | — | $873.00M | — | ||||
| Evenity | — | $350.00M | $530.00M | — | ||||
| Sensipar | — | — | — | — | ||||
| Blincyto | — | — | $472.00M | $336.00M | ||||
| Tezspire | — | — | — | $170.00M | ||||
| Total | $23.36B | $25.42B | $25.98B | $26.32B |
Amgen brought in $26.32B from its eight product and service lines in fiscal 2022, the year ended December 31, 2022. Amgen regrouped these lines after fiscal 2021, so the total does not compare directly with that year's $25.98B. Product Sales was the largest at $17.74B (67.4%), ahead of Enbrel at $4.04B (15.4%) and Xgeva at $1.48B (5.6%). The other five lines brought in $3.06B combined.
Compared with fiscal 2021, every line above 2% of revenue shrank. Enbrel held up best, down 9.4% to $4.04B, and Other Revenues fell the most, down 49.3% to $852.00M.
Amgen began breaking out Product Sales in fiscal 2022, Blincyto in fiscal 2021 and Tezspire in fiscal 2022. Amgen stopped reporting Other Products ($5.71B in fiscal 2021), Enbrel® (Etanercept) ($5.00B in fiscal 2020), Prolia ($3.25B in fiscal 2021) and 10 others as separate lines.
Amgen (AMGN) reports its revenue by geography, by customer and by product and service. In fiscal 2025, U.S was its largest region, bringing in $26.42B (71.9% of the total), followed by Row at $10.33B (28.1%).
U.S was Amgen's largest region in fiscal 2025, bringing in $26.42B, or 71.9% of the $36.75B total across its two regions.
Mckesson Corporation was Amgen's largest revenue line in fiscal 2024, bringing in $22.17B, or 66.3% of the $33.45B total across its two revenue lines.
Product Sales was Amgen's largest product and service line in fiscal 2022, bringing in $17.74B, or 67.4% of the $26.32B total across its eight product and service lines.
U.S grew faster than Row in fiscal 2025, up 10.7% from $23.86B to $26.42B. Row grew 8.1% to $10.33B.
Every figure comes from Amgen's annual financial filings, as reported. Each line keeps the name Amgen gives it, and years follow its fiscal calendar.
Amgen's revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.